151 related articles for article (PubMed ID: 18292607)
1. Cholesterol in end-stage renal disease: the good, the bad or the ugly?
Diepeveen SH; Wetzels JF; Bilo HJ; van Tits LJ; Stalenhoef AF
Neth J Med; 2008 Feb; 66(2):53-61. PubMed ID: 18292607
[TBL] [Abstract][Full Text] [Related]
2. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure.
Baber U; Toto RD; de Lemos JA
Am Heart J; 2007 Apr; 153(4):471-7. PubMed ID: 17383281
[TBL] [Abstract][Full Text] [Related]
3. Inflammation and oxidative stress in ESRD--the role of myeloperoxidase.
Maruyama Y; Lindholm B; Stenvinkel P
J Nephrol; 2004; 17 Suppl 8():S72-6. PubMed ID: 15599890
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy.
Diepeveen SH; Verhoeven GH; van der Palen J; Dikkeschei BL; van Tits LJ; Kolsters G; Offerman JJ; Bilo HJ; Stalenhoef AF
Nephron Clin Pract; 2004; 98(1):c3-7. PubMed ID: 15361698
[TBL] [Abstract][Full Text] [Related]
5. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy.
Stenvinkel P; Diczfalusy U; Lindholm B; Heimbürger O
Nephrol Dial Transplant; 2004 Apr; 19(4):972-6. PubMed ID: 15031358
[TBL] [Abstract][Full Text] [Related]
6. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease.
Dummer CD; Thome' FS; Zingano B; Lindoso A; Veronese FV
J Nephrol; 2008; 21(6):900-8. PubMed ID: 19034875
[TBL] [Abstract][Full Text] [Related]
7. Time for new indications for statins?
Banach M; Mikhailidis DP; Kjeldsen SE; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS1-5. PubMed ID: 19946240
[TBL] [Abstract][Full Text] [Related]
8. Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure.
Ivanovski O; Szumilak D; Nguyen-Khoa T; Nikolov IG; Joki N; Mothu N; Maizel J; Westenfeld R; Ketteler M; Lacour B; Drüeke TB; Massy ZA
J Urol; 2008 Apr; 179(4):1631-6. PubMed ID: 18295249
[TBL] [Abstract][Full Text] [Related]
9. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg?
Himmelfarb J
Semin Dial; 2004; 17(6):449-54. PubMed ID: 15660575
[TBL] [Abstract][Full Text] [Related]
10. [Malnutrition -- inflammation -- atherosclerosis (MIA syndrome) in patients with renal failure].
Pawlaczyk K; Oko A; Lindholm B; Czekalski S
Pol Merkur Lekarski; 2003 Oct; 15(88):334-41; discussion 341-3. PubMed ID: 14974361
[TBL] [Abstract][Full Text] [Related]
11. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease.
Stenvinkel P
J Ren Nutr; 2003 Apr; 13(2):144-8. PubMed ID: 12671839
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
Shojaei MH; Djalali M; Siassi F; Khatami MR; Boroumand MA; Eshragian MR
Iran J Kidney Dis; 2009 Jul; 3(3):141-4. PubMed ID: 19617662
[TBL] [Abstract][Full Text] [Related]
13. Management of lipid abnormalities associated with end-stage renal disease.
Liu J; Kalantarinia K; Rosner MH
Semin Dial; 2006; 19(5):391-401. PubMed ID: 16970739
[TBL] [Abstract][Full Text] [Related]
14. The cholesterol paradox is flawed; cholesterol must be lowered in dialysis patients.
Wan RK; Mark PB; Jardine AG
Semin Dial; 2007; 20(6):504-9. PubMed ID: 17991195
[TBL] [Abstract][Full Text] [Related]
15. Statin effects in CKD: is there a "point of no return"?
Wanner C
Am J Kidney Dis; 2009 May; 53(5):723-5. PubMed ID: 19393469
[No Abstract] [Full Text] [Related]
16. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
17. Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients.
Suliman ME; Stenvinkel P; Bárány P; Rashid Qureshi A; Lindholm B
Semin Nephrol; 2006 Jan; 26(1):14-9. PubMed ID: 16412819
[TBL] [Abstract][Full Text] [Related]
18. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
[TBL] [Abstract][Full Text] [Related]
19. Reverse epidemiology: paradoxical observations in haemodialysis patients.
Nurmohamed SA; Nubé MJ
Neth J Med; 2005 Nov; 63(10):376-81. PubMed ID: 16301758
[TBL] [Abstract][Full Text] [Related]
20. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
Vaziri ND; Norris KC
Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
